Biljana Naumovic is the Worldwide Vice President, Global Commercial Strategy, Oncology for the Janssen Pharmaceutical Companies of Johnson & Johnson. Working in collaboration with Janssen Research & Development, she is responsible for the development of breakthrough commercial strategies to deliver a sustainable and differentiated oncology pipeline. In this role, she oversees multiple functions that support the Global Oncology business such as Strategic Marketing, Market Access, Medical Affairs, Portfolio, and Strategic Analytics.
Prior to this appointment, Biljana held the position of Managing Director, Janssen Australia & New Zealand (Janssen-Cilag Pty Ltd.) where she oversaw a cultural transformation and reorganization of the business, culminating in double digit growth in 2021. Biljana first joined Janssen in 2019 as Vice President, Oncology for Europe, the Middle East and Africa (EMEA), where she was responsible for creating and delivering the commercial strategy across the solid tumor portfolio and pipeline spanning prostate cancer, bladder cancer, and lung cancer, as well as multiple novel tumor pathways.
Before joining Janssen, Biljana held a number of senior positions at AstraZeneca, most recently Vice President of Commercial for Europe where she was, responsible for strategy across oncology, respiratory and cardio metabolic therapy throughout Europe, including commercial effectiveness and digital platforms.
Biljana is a physician by training and graduated in 2001 from the Belgrade University Medical School. She worked as a practicing physician for several years before transitioning to industry. Biljana also holds an executive education degree from the London Business School.